Centro De Ingenieria Genetica Y Biotecnologia

Jorge Berlanga Acosta

Diana Garcia Del Barco Herrera

Gerardo Enrique Guillen Nieto

Mario Pablo Estrada Garcia

Gerardo Enrique Guillén Nieto

Julio Raul Fernandez Masso

Danay Cibrian Vera

Rebeca Martinez Rodriguez

Ernesto Lopez Mola

Manuel Selman-Housein Sosa

Mariela Vazquez Castillo

José Suarez Alba

Isabel Guillen Perez

Jose Suarez Alba

Diana García Del Barco Herrera

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

Method for controlling fibrosis and other pathological deposits in tissues comprising administering a GHRP-6 composition

This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods. The combination is useful as a prophylactic agent in those subjects prone to multiple organ failure (MOF) such as burn victims, multiple trauma patients, hypoxic neonates, acute respiratory distress syndrome patients, and necrotizing enterocolitis patients.

Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect

Growing community of inventors

Ciudad de la Habana, Cuba

Jorge Berlanga Acosta